<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B4C4AD26-BA5A-40A3-B630-8E56BB3D17CD"><gtr:id>B4C4AD26-BA5A-40A3-B630-8E56BB3D17CD</gtr:id><gtr:name>University Hospital Motol</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/36DE8DC4-48F5-4CBF-A307-3AE21CDE1745"><gtr:id>36DE8DC4-48F5-4CBF-A307-3AE21CDE1745</gtr:id><gtr:name>Optibiotix Health plc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B92C1E49-4D20-4A69-BDBE-BDEC1AE2A476"><gtr:id>B92C1E49-4D20-4A69-BDBE-BDEC1AE2A476</gtr:id><gtr:name>University Medical Centre Utrecht</gtr:name><gtr:address><gtr:line1>Unversity Medical Centre Utrecht</gtr:line1><gtr:line2>Rudolf Magnus Institute for Neuroscience</gtr:line2><gtr:line3>PO Box 85060</gtr:line3><gtr:postCode>NL-3508 AB</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2A80FFDA-3B8B-43BA-80C3-3AA850B49BA1"><gtr:id>2A80FFDA-3B8B-43BA-80C3-3AA850B49BA1</gtr:id><gtr:name>University of the West of England</gtr:name><gtr:address><gtr:line1>Coldharbour Lane</gtr:line1><gtr:line2>Frenchay</gtr:line2><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS16 1QY</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B42BE007-89B2-4617-B3D9-FD5EE9E56A9D"><gtr:id>B42BE007-89B2-4617-B3D9-FD5EE9E56A9D</gtr:id><gtr:name>Teagasc Food Research Centre</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5904176C-7486-4E2B-959A-94C29ADE4D96"><gtr:id>5904176C-7486-4E2B-959A-94C29ADE4D96</gtr:id><gtr:name>University of Brighton</gtr:name><gtr:department>Sch of Pharmacy &amp; Biomolecular Sciences</gtr:department><gtr:address><gtr:line1>Cockcroft Building M24</gtr:line1><gtr:line2>Lewes Road</gtr:line2><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN2 2GJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5904176C-7486-4E2B-959A-94C29ADE4D96"><gtr:id>5904176C-7486-4E2B-959A-94C29ADE4D96</gtr:id><gtr:name>University of Brighton</gtr:name><gtr:address><gtr:line1>Cockcroft Building M24</gtr:line1><gtr:line2>Lewes Road</gtr:line2><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN2 2GJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B4C4AD26-BA5A-40A3-B630-8E56BB3D17CD"><gtr:id>B4C4AD26-BA5A-40A3-B630-8E56BB3D17CD</gtr:id><gtr:name>University Hospital Motol</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A8967420-49D3-4509-9912-25FB3EC75B74"><gtr:id>A8967420-49D3-4509-9912-25FB3EC75B74</gtr:id><gtr:name>University of Sussex</gtr:name><gtr:address><gtr:line1>The Administration</gtr:line1><gtr:line2>Sussex House</gtr:line2><gtr:line3>Falmer</gtr:line3><gtr:line4>Brighton</gtr:line4><gtr:line5>East Sussex</gtr:line5><gtr:postCode>BN1 9RH</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/36DE8DC4-48F5-4CBF-A307-3AE21CDE1745"><gtr:id>36DE8DC4-48F5-4CBF-A307-3AE21CDE1745</gtr:id><gtr:name>Optibiotix Health plc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B92C1E49-4D20-4A69-BDBE-BDEC1AE2A476"><gtr:id>B92C1E49-4D20-4A69-BDBE-BDEC1AE2A476</gtr:id><gtr:name>University Medical Centre Utrecht</gtr:name><gtr:address><gtr:line1>Unversity Medical Centre Utrecht</gtr:line1><gtr:line2>Rudolf Magnus Institute for Neuroscience</gtr:line2><gtr:line3>PO Box 85060</gtr:line3><gtr:postCode>NL-3508 AB</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2A80FFDA-3B8B-43BA-80C3-3AA850B49BA1"><gtr:id>2A80FFDA-3B8B-43BA-80C3-3AA850B49BA1</gtr:id><gtr:name>University of the West of England</gtr:name><gtr:address><gtr:line1>Coldharbour Lane</gtr:line1><gtr:line2>Frenchay</gtr:line2><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS16 1QY</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B42BE007-89B2-4617-B3D9-FD5EE9E56A9D"><gtr:id>B42BE007-89B2-4617-B3D9-FD5EE9E56A9D</gtr:id><gtr:name>Teagasc Food Research Centre</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/086618B1-2F00-4C98-97B1-71F22E95E4A2"><gtr:id>086618B1-2F00-4C98-97B1-71F22E95E4A2</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:otherNames>Vaughan</gtr:otherNames><gtr:surname>Jones</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901553"><gtr:id>E38BD023-845D-4F0E-ADE9-7821C246A1AC</gtr:id><gtr:title>Bile acid modification by the human gut microbiota and its role in pathogenesis of colorectal cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901553</gtr:grantReference><gtr:abstractText>The human gut is home to a wide range of bacteria, and every adult harbours around 100 trillion microbial cells in their intestines belonging to hundreds of bacterial species. This population of bacteria is referred to as the gut microbiota, and these bacteria are thought to undertake numerous beneficial activities. However some of the activities undertaken by the gut microbiota may be involved in the development of colorectal cancer (CRC). 
Diet, and in particular a high intake of animal fat and red meat, has been identified as a major risk factor for CRC, but it is not yet clear how these dietary factors lead to the development of CRC. It is important for us to understand the causes of diseases like CRC, in order to develop effective treatments or identify ways in which the disease could be prevented altogether.
Recent studies have indicated that the gut microbiota may be an important factor in the influence of diet on CRC risk, and in particular the ability of gut microbes to modify components of bile, called bile acids. Bile acids are naturally produced by our bodies to help us digest the fat contained within the food we eat, and a diet rich in fat results in a increased level of bile acid in the intestine. Bile acids are readily converted to different forms by the gut microbiota, and some of these altered bile acids may be carcinogenic and affect the expression of genes thought to be important in the development of CRC.
The purpose of this study is to investigate the relationship between the modification of bile acids by gut bacteria and development of CRC, to determine how these microbes may cause this disease. By comparing the gut bacteria of individuals with CRC and those who are healthy, we will be able to identify any association between activities of these microbes and risk of disease. Subsequently we will be able to look at the effect of these bacteria on specific human genes known to be associated with CRC, which will allow us to identify the how gut bacteria may trigger development of CRC.</gtr:abstractText><gtr:technicalSummary>CRC is the third most common malignancy worldwide and it is estimated that more than 100 new cases are diagnosed daily in the UK. The incidence of this disease worldwide has risen from ~500,000 new cases in 1975 to over a million new cases in 2002. Acquisition and pathogenesis of sporadic CRC is complex and multifactorial. While diet has consistently been associated with an increased risk of CRC, the underlying mechanisns which result in genetic damage and carcinogenesis are poorly understood. There is increasing evidence that the indigenous gut microbial population is a significant factor in the pathogenesis of CRC, and that this community mediates the effects of diet on colonic health. 
In particular microbial bile acid modification is emerging as a key activity through which the gut microbial population and dietary factors interact to initiate CRC or enhance its progression. The products of microbial bile acid metabolism have been proposed to act as carcinogens and activate pro-inflammatory regulators such as NF-kB and COX-2 which result in the inhibition of apoptosis and the survival of malignant cells. Recent studies have also indicated that the capacity for bile acid modification may vary between the gut microbial populations of different individuals, and if so this could relate to overall risk of CRC acquisition. 
The overall aim of this project is to identify any relationship between the capacity for bile acid modification in the human gut microbiota and acquisition of colorectal cancer. The capacity for bile acid metabolism in the gut microbiomes of healthy individuals, and those with CRC and pre-cancerous polyps will be determined and compared. The contribution of microbial bile salt hydrolase (BSH) upon activation of key host encoded genes (NF-kB and COX-2) involved in inflammation, inhibition of apoptosis, and acquisition of CRC will be established. Ultimately this will clarify the relationship between microbial bile acid metabolism and CRC, and elucidate underlying mechanisms of disease.</gtr:technicalSummary><gtr:fund><gtr:end>2014-05-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>403822</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital Motol</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:department>Surgery Department - 2nd Medical Faculty</gtr:department><gtr:description>University Hospital Motol, Prague, Czech Rep.</gtr:description><gtr:id>460F8040-5B21-4C0C-97D9-570812EF07C5</gtr:id><gtr:impact>Initiated collection of stool human stool samples form Czech republic. Current 10 samples have been acquired comprising a mixture of healthy, poly and CRC samples. Collection is continuing at UHM. This collaboration is between clinical and academic partners.</gtr:impact><gtr:outcomeId>FsgCCNHtppw-1</gtr:outcomeId><gtr:partnerContribution>The provision of stool samples is vital to the element of the project concerned with analysis of the gut microbiome and capacity for bile acid modification in health and disease. Access to patient samples from Czech republic not only helps deliver original project aims, but also provides an added dimension in access to samples from a geographically distinct region.</gtr:partnerContribution><gtr:piContribution>Collaborators at UHM, Prague are currently collecting stool samples from individuals with intestinal polyps, colorectal cancer, and healthy controls. Documentation required for ethical approval was prepared by my team in consultation with Czech partners, and samples will be shipped to my laboratory for analysis of the gut microbiome.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Optibiotix Health plc</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Optibiotix bile acid modification by probiotics</gtr:description><gtr:id>73EF87FF-EDFF-42C4-AA7F-50D9217F7018</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>58a1812e89bfb4.32894588-1</gtr:outcomeId><gtr:partnerContribution>Optibiotix have offered funding for preliminary studies, and have offered to fund 2 PhD studentships proposed to begin 2017/2018.</gtr:partnerContribution><gtr:piContribution>Based on our work in the field of microbial bile acid modification we have begun working with a company (Optibiotix) who develop probiotic products. Our role in this collaboration will be to help understand the mechanisms underlying bile acid modification by these probiotics and how this contribute to their probiotic effect.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sussex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Life Sciences Sussex</gtr:department><gtr:description>Metabolomics, Liz Hill, Sussex</gtr:description><gtr:id>5E35F5CF-F72F-4552-9865-BC4FBD05A8BE</gtr:id><gtr:impact>Methods for metabolite extraction have been optimised and processing of stool samples is ongoing. This involves a multi-disceplinary collaboration between microbiologist, molecular biologists, and chemists.</gtr:impact><gtr:outcomeId>XoUk3bekK1N-1</gtr:outcomeId><gtr:partnerContribution>Collaborators will help us to realise a key element of the project directed towards analysis of bile acid species present in stool samples. When combined with data regarding the microbiome this will permit us to better understand changes in capacity for bile acid modification in health and disease. However, collaborators will also be able to expand this analysis to the metabolome as a whole provide significant more insight and potentially allowing us to identify other disease biomarkers.</gtr:partnerContribution><gtr:piContribution>This collaboration facilitates analysis of the capacity for bile acid metabolism in the human gut microbiome. My team is coordinating the collection and preparation of human stool samples, and will undertake analysis of the microbiome. Collaborators at UoS will analyse the faecal metabolome.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Teagasc Food Research Centre</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:description>16S pyro sequencing and shotgun metagenomes - Paul Cotter</gtr:description><gtr:id>2F668A0F-2A38-4A96-9EE6-4181A586A9D2</gtr:id><gtr:impact>This collaboration has so far allowed us to optimise methods for metagenomic DNA extraction and 16S rRNA gene amplification from stool samples. We have now generated in depth 16S sequence data from 61 stool samples and are presently analysing the data. We are also in the process of generating full shotgun metagenomes fro 15 samples (5 per group).</gtr:impact><gtr:outcomeId>aqQ9yjgHyLg-1</gtr:outcomeId><gtr:partnerContribution>My team will undertake sample processing and preparation, with collaborators providing access to pyro-sequencing facilities to provide 16S sequences. We now also have the opportunity ti generate shotgun metagenomes of a subset of samples. Both groups will participate in data analysis.</gtr:partnerContribution><gtr:piContribution>This collaboration will afford a considerably more detailed and in depth survey of gut microbiome composition in health and disease, than originally intended.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of the West of England</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Genome signatures - UWE</gtr:description><gtr:id>19728132-22E0-4208-90CC-41E1801F868B</gtr:id><gtr:impact>no outputs yet</gtr:impact><gtr:outcomeId>56af4abd26a8e2.29372069-1</gtr:outcomeId><gtr:partnerContribution>Expertise in bioinformatics.</gtr:partnerContribution><gtr:piContribution>We are working with colleague at UWE to further develop and apply genome signature based tools of analysis of metagenomes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Medical Center Utrecht (UMC)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>UMC Utrecht metagenomic libraires</gtr:description><gtr:id>531EED40-8F65-4462-BECE-3F4E04C8D354</gtr:id><gtr:impact>Prelimianry data from screening of these libriares has been presented at the Human Microbiome Conference 2011, Vancouver, Canada.

A manuscript resulting from this collaboration has now been published in The Journal of Antimicrobial Chemotherapy (Buelow et al 2014 PMID: 24710024)</gtr:impact><gtr:outcomeId>GQkPG6YVG5p-1</gtr:outcomeId><gtr:partnerContribution>This collaboration will allow us to access new methods and techniques to explore the gut microboiome not currently avasilable through exisiting collaborations defined in the original proposal.</gtr:partnerContribution><gtr:piContribution>Provided knowledge, and triaing for the construction of large instert metagneomic libraries from the human gut microboota for a research group based at UMC Utrecht</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Yakut HCP study day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6A420FC5-D4B7-4EFE-8127-D1F8C877E764</gtr:id><gtr:impact>Invited to participate in the Yakult sponsored study day for healthcare practitioners, and cover the topic of probiotics and cancer. NB: invitation to participate has been accepted but the event is not scheduled to take place until 20th October 2016</gtr:impact><gtr:outcomeId>56af4d04bac852.45565300</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Education Meeting fro Nursing staff (Royal Sussex County Hospital)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2AE962D3-EDDC-481A-84F7-F2E28DE49D90</gtr:id><gtr:impact>Presented current understanding on the human gut microbiome, including preliminary data from our MRC funded research to nursing staff at the Royal Sussex Country Hospital. Run as inform presentation and discussion group covering what our work may mean, and wider work in the area of the human gut microbiome on the diagnosis, treatment and management of disease. Helped healthcare staff engage with and take onboard new scientific knowledge in this area and understand how this may eventually impact on their work - as well as discussing how they can become more involved in the research process.

Nursing staff indicated that this gave them a greater understanding and awareness of research in this area, and also increased interest in becoming involved in aspects of research in this area. Staff indicated this knowledge will also be useful in answering patient queries on related fields such as use of probiotics.</gtr:impact><gtr:outcomeId>BiEL8TYDqvg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science News Interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1556FF70-4D28-4956-AA7E-80AEC6CB4AD4</gtr:id><gtr:impact>Interview with Journalist from Science News (Washington DC, USA) regarding human gut microbiome research and in particular the human gut virome.

International dissemination of our research to a a broad audience including the general public.</gtr:impact><gtr:outcomeId>UVpM6QyzAas</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>https://www.sciencenews.org</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hospital visit and presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6AC8EF3E-24B9-4783-B2D9-A333AA18984E</gtr:id><gtr:impact>Gave a tlak to hospital staff regarding the gut microbiota and coclon cancer.

Staff indicated that they had gained an intertesing insiht to this field and were keen to participate in research of this nature.</gtr:impact><gtr:outcomeId>APHedjvUT6S</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alternatives to Antibiotics working group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7D495C9D-82D8-4E2D-8CD5-653BEC47347D</gtr:id><gtr:impact>Member of the alternatives to antibiotics working party organised by the Wellcome Trust and Dept of Health to review status of alternatives portfolio and suggest priority areas for funding.</gtr:impact><gtr:outcomeId>56af4de8cdc363.65293246</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:url>http://www.wellcome.ac.uk/News/Media-office/Press-releases/2016/WTP060091.htm</gtr:url><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NComms press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D43D10EE-BB39-4CB4-BF38-BBA9A78C8651</gtr:id><gtr:impact>Press release regarding work published in Ogilvie et al 2013 PMID 24036533. Results have still not been ascertained, but one invitation for interview was received shortly after.

Dissemination of research findings to a wide audience</gtr:impact><gtr:outcomeId>MkS2go6RMaY</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.brighton.ac.uk/news/2013/130918understanding_viruses.php?PageId=810&amp;dm_i=1RM7,1V6AH,A8104B,6OPTX,1</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>News article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>63E9198B-448A-4FFB-898B-20CC40E4F569</gtr:id><gtr:impact>News article describing research in local news paper

NA</gtr:impact><gtr:outcomeId>kj4vj667BWp</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>55000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Brighton Doctoral Training Scholarships</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>University of Brighton</gtr:fundingOrg><gtr:id>B37ACB7B-E1C4-4592-985A-C124D3C38781</gtr:id><gtr:outcomeId>XFXfSdW99DS</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>55000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Internal PhD studentship</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>University of Brighton</gtr:fundingOrg><gtr:id>11D09D63-0100-45A9-BC60-567677E8376B</gtr:id><gtr:outcomeId>N1jznMVdSGX</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Challenges</gtr:description><gtr:end>2013-11-02</gtr:end><gtr:fundingOrg>University of Brighton</gtr:fundingOrg><gtr:id>27A050BF-3436-4B91-959F-7945AF96AA6C</gtr:id><gtr:outcomeId>YCT6wgyHeJo</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>71914</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Dunhill Medical Trust Proof of Concept award</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>The Dunhill Medical Trust</gtr:fundingOrg><gtr:fundingRef>R394/1114</gtr:fundingRef><gtr:id>AE815F5F-DA2F-4902-918C-EC5757151342</gtr:id><gtr:outcomeId>56af4c1ac3c578.37045159</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1200</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SfAM Presidents Fund</gtr:description><gtr:end>2011-11-02</gtr:end><gtr:fundingOrg>Society for Applied Microbiology</gtr:fundingOrg><gtr:id>AB131F9F-135E-4DD7-BBE7-6FC3A5C03195</gtr:id><gtr:outcomeId>Lc4tEVgd3XK</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>443000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Developmental Pathways Funding Scheme (Biomedical Catalyst)</gtr:description><gtr:end>2019-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N006496/1</gtr:fundingRef><gtr:id>A8801161-99E4-439F-9745-1F2300B60B3C</gtr:id><gtr:outcomeId>56af4b88e45c70.83243782</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Alternatives 2 antibiotics Wellcome Trust and DoH commissioned policy document</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>85B8FD2B-86B3-466A-B864-298C2226B005</gtr:id><gtr:outcomeId>545b9857a4e869.89576297</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>SfAM HoC Select S&amp;amp;T common ABR</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F905E0F6-66B3-4617-8996-4D67A0D05235</gtr:id><gtr:outcomeId>j1eitCoBEYp</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have begun devleoping a collection fo stool samples from patients with colorectal cancer, polyposis and healthy controls, along with information of generla diet and weight. Furthermore, we have also formed a collaboration with research groups in Czech republic to aquire siilar samples from this country also.</gtr:description><gtr:id>C74D2DC4-C20E-4380-B779-D0B324C43E09</gtr:id><gtr:impact>Work usng these smaples is currently ongoign and impacts will not be apparent until later int he project. However these material allow a wide range of research project to be pursed in our lab, and the aquisition of samples from countries outsde the UK in particular will faciliate more effective comparisions of gut microbiomes related to colorectal cancer, between countries.</gtr:impact><gtr:outcomeId>HWvThQX7aJd</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Human faecal samples collection</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Developed new approaches for analysis metagenomic datasets which will be and have already been highly beneficial in our research. This was developed in response the the large number of sequence that are of unknown phylogenetic affiliation in any give metagenomic dataset, impeding analysis. Our new approach proves a strategy which can help classify metagenomic sequences and was validated by dissection of viral sequences from existing gut metagenomes, and provided an indication of their bacterial host range. This also revealed the potential existence of &amp;quot;viral enterotypes&amp;quot; in the gut microbiome.</gtr:description><gtr:id>9BE742B6-7E46-420B-8850-78B6CF5E28D7</gtr:id><gtr:impact>This has allowed us to initiate work aimed at understanding relatively unexplored facets of the human gut microbiome and how this may related to risk/progression/diagnosis of disease such as CRC.</gtr:impact><gtr:outcomeId>awAXKJin72K</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Genome Signtnature analysis for metagenomes</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.nature.com/ncomms/2013/130916/ncomms3420/full/ncomms3420.html</gtr:url></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>839156F8-9EC4-4A7A-838A-707B20C8ED06</gtr:id><gtr:title>Effects of selective digestive decontamination (SDD) on the gut resistome.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ab4bebf0162f06545341f21811d34814"><gtr:id>ab4bebf0162f06545341f21811d34814</gtr:id><gtr:otherNames>Buelow E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>545743746d4290.99998904</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23AEDF00-D5B9-4E3E-862B-234EA333B676</gtr:id><gtr:title>Evolutionary, ecological and biotechnological perspectives on plasmids resident in the human gut mobile metagenome.</gtr:title><gtr:parentPublicationTitle>Bioengineered bugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49258fb0445e5deba7ddee01aa30a92c"><gtr:id>49258fb0445e5deba7ddee01aa30a92c</gtr:id><gtr:otherNames>Ogilvie LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1949-1018</gtr:issn><gtr:outcomeId>g1eCoCnUwXp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A1C6CBB-2D8D-4957-91B3-6F395036BE37</gtr:id><gtr:title>Selection of DNA aptamers against uropathogenic Escherichia coli NSM59 by quantitative PCR controlled Cell-SELEX.</gtr:title><gtr:parentPublicationTitle>Journal of microbiological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee87351111b240a8af65298b32d856c2"><gtr:id>ee87351111b240a8af65298b32d856c2</gtr:id><gtr:otherNames>Savory N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-7012</gtr:issn><gtr:outcomeId>545743744a40f4.52267461</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>483346D4-3E1A-40B0-B603-B6D3E531B7B4</gtr:id><gtr:title>Genome signature-based dissection of human gut metagenomes to extract subliminal viral sequences.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49258fb0445e5deba7ddee01aa30a92c"><gtr:id>49258fb0445e5deba7ddee01aa30a92c</gtr:id><gtr:otherNames>Ogilvie LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_13771_21_24036533</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7AC0BC6-580E-479E-862F-64B3BCD30A7B</gtr:id><gtr:title>Resolution of habitat-associated ecogenomic signatures in bacteriophage genomes and application to microbial source tracking.</gtr:title><gtr:parentPublicationTitle>The ISME journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49258fb0445e5deba7ddee01aa30a92c"><gtr:id>49258fb0445e5deba7ddee01aa30a92c</gtr:id><gtr:otherNames>Ogilvie LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1751-7362</gtr:issn><gtr:outcomeId>5a982b8ca959b8.35349320</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18CC50EF-372B-4E99-A128-9E524E31CA92</gtr:id><gtr:title>In silico maturation of binding-specificity of DNA aptamers against Proteus mirabilis.</gtr:title><gtr:parentPublicationTitle>Biotechnology and bioengineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee87351111b240a8af65298b32d856c2"><gtr:id>ee87351111b240a8af65298b32d856c2</gtr:id><gtr:otherNames>Savory N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-3592</gtr:issn><gtr:outcomeId>pm_13771_21_23568752</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49A5A086-15AF-4C74-A5A4-9F8DB7929593</gtr:id><gtr:title>The human gut virome: a multifaceted majority.</gtr:title><gtr:parentPublicationTitle>Frontiers in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49258fb0445e5deba7ddee01aa30a92c"><gtr:id>49258fb0445e5deba7ddee01aa30a92c</gtr:id><gtr:otherNames>Ogilvie LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1664-302X</gtr:issn><gtr:outcomeId>56af48e3d2dd66.75065188</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>619581F3-011E-4BD5-8C3A-3762C19E95CF</gtr:id><gtr:title>Evaluation of environmental scanning electron microscopy for analysis of Proteus mirabilis crystalline biofilms in situ on urinary catheters.</gtr:title><gtr:parentPublicationTitle>FEMS microbiology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/464266758047e2e4eed33d975e623d90"><gtr:id>464266758047e2e4eed33d975e623d90</gtr:id><gtr:otherNames>Holling N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0378-1097</gtr:issn><gtr:outcomeId>5457442a9c70d8.69925458</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E95E9148-9AE9-4DA2-97E1-CB95CEEA14C5</gtr:id><gtr:title>Identification of aminoglycoside and ?-lactam resistance genes from within an infant gut functional metagenomic library.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b645dd5f9cf2ea753607b97ce592b09"><gtr:id>7b645dd5f9cf2ea753607b97ce592b09</gtr:id><gtr:otherNames>Fouhy F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5457437421e031.47001101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BA15A83-1FD9-47DD-B0AE-13A2512D82A9</gtr:id><gtr:title>Comparative (meta)genomic analysis and ecological profiling of human gut-specific bacteriophage fB124-14.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49258fb0445e5deba7ddee01aa30a92c"><gtr:id>49258fb0445e5deba7ddee01aa30a92c</gtr:id><gtr:otherNames>Ogilvie LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13771_21_22558115</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80D7A31F-D683-47F0-A490-8BC6A4F7D75B</gtr:id><gtr:title>Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease?</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49258fb0445e5deba7ddee01aa30a92c"><gtr:id>49258fb0445e5deba7ddee01aa30a92c</gtr:id><gtr:otherNames>Ogilvie LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>pm_13771_21_22490526</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>190BA5F9-F64A-4174-AF59-275A3104CC88</gtr:id><gtr:title>Disruption of Escherichia coli Nissle 1917 K5 capsule biosynthesis, through loss of distinct kfi genes, modulates interaction with intestinal epithelial cells and impact on cell health.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a41a4eaf2c824f18dec4ecb5cd581c8c"><gtr:id>a41a4eaf2c824f18dec4ecb5cd581c8c</gtr:id><gtr:otherNames>Nzakizwanayo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_55f985985360f2fe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8068365-C4B8-481E-AD5C-067A014EA5FF</gtr:id><gtr:title>Escherichia coli Nissle 1917 enhances bioavailability of serotonin in gut tissues through modulation of synthesis and clearance.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a41a4eaf2c824f18dec4ecb5cd581c8c"><gtr:id>a41a4eaf2c824f18dec4ecb5cd581c8c</gtr:id><gtr:otherNames>Nzakizwanayo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56af4939b433c2.08937949</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4555F86F-3541-4B7C-858C-EB55394A4100</gtr:id><gtr:title>Bacterial bile acid modification and potential pharmaceutical applications</gtr:title><gtr:parentPublicationTitle>Journal fo Applied Therpeutic Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c9c2f240860decb15c8314ea44bbfe03"><gtr:id>c9c2f240860decb15c8314ea44bbfe03</gtr:id><gtr:otherNames>Jones Brian</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>r7Z1Px4mQ8H</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40219740-81A7-4C45-A446-793940AF09DF</gtr:id><gtr:title>Elucidating the genetic basis of crystalline biofilm formation in Proteus mirabilis.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/464266758047e2e4eed33d975e623d90"><gtr:id>464266758047e2e4eed33d975e623d90</gtr:id><gtr:otherNames>Holling N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>5457442ac77a00.01179676</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901553</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>